How big is the de-identified health data market?

The global de-identified health data market size was estimated at USD 8.80 billion in 2025 and is expected to reach USD 9.58 billion in 2026.

What is the de-identified health data market growth?

The global de-identified health data market is expected to grow at a compound annual growth rate of 9.37% from 2026 to 2033 to reach USD 17.93 billion by 2033.

Which segment accounted for the largest de-identified health data market share?

North America dominated the global de-identified health data market with a share of 35.3% in 2025. This is attributable to the presence of leading pharmaceutical and biotech companies, advanced healthcare infrastructure and significant technological investment, particularly in data analytics and AI. In addition, stringent regulatory frameworks such as HIPAA enhance the focus on data privacy, encouraging the use of de-identified data for research while ensuring compliance.

Who are the key players in de-identified health data market?

Some key players operating in the global de-identified health data market include IQVIA; Oracle (Cerner Corporation); Merative (Truven Health Analytics); Optum, Inc. (UnitedHealth Group); ICON plc; Veradigm LLC (Formerly known as Allscripts); IBM; Flatiron Health (F. Hoffmann-La Roche Ltd); Premier, Inc.; Shaip; Komodo Health, Inc.; Evidation Health, Inc.; Medidata; Clarify Health Solutions; and Satori Cyber Ltd.

What are the factors driving the de-identified health data market?

Key factors that are driving the market growth include rising demand for healthcare data, growth in AI and Machine Learning, growing adoption of healthcare analytics (data-driven decision-making), and growth in Real-World Data (RWD) and Real-World Evidence (RWE).